Tilray Brands, Inc. (TLRY)
NASDAQ: TLRY · Real-Time Price · USD
6.56
-0.33 (-4.79%)
At close: Apr 28, 2026, 4:00 PM EDT
6.53
-0.03 (-0.46%)
Pre-market: Apr 29, 2026, 8:17 AM EDT
Tilray Brands Revenue
Tilray Brands had revenue of $206.73M in the quarter ending February 28, 2026, with 11.28% growth. This brings the company's revenue in the last twelve months to $858.28M, up 3.82% year-over-year. In the fiscal year ending May 31, 2025, Tilray Brands had annual revenue of $821.31M with 4.10% growth.
Revenue (ttm)
$858.28M
Revenue Growth
+3.82%
P/S Ratio
0.91
Revenue / Employee
$301,997
Employees
2,842
Market Cap
782.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2025 | 821.31M | 32.37M | 4.10% |
| May 31, 2024 | 788.94M | 161.82M | 25.80% |
| May 31, 2023 | 627.12M | -1.25M | -0.20% |
| May 31, 2022 | 628.37M | 115.29M | 22.47% |
| May 31, 2021 | 513.09M | 107.76M | 26.59% |
| May 31, 2020 | Pro | Pro | Pro |
| May 31, 2019 | Pro | Pro | Pro |
| May 31, 2018 | Pro | Pro | Pro |
| May 31, 2017 | Pro | Pro | Pro |
| May 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evotec SE | 925.65M |
| Collegium Pharmaceutical | 780.57M |
| Pacira BioSciences | 726.41M |
| Amphastar Pharmaceuticals | 719.89M |
| Alvotech | 588.90M |
| Esperion Therapeutics | 403.14M |
| Ironwood Pharmaceuticals | 296.15M |
| Cronos Group | 146.59M |
TLRY News
- 5 days ago - 'Big Business Opportunity': Cannabis CEO Celebrates DOJ Easing Regulations On Medical Marijuana - Forbes
- 5 days ago - The cannabis rescheduling is causing celebration — and confusion — as marijuana stocks sell off - Market Watch
- 5 days ago - Cannabis Stocks Soared—Than Sank. Here's What Investors Need to Know. - Investopedia
- 5 days ago - Cannabis rescheduling fuels optimism across industry - Reuters
- 5 days ago - Tilray stock price soars as we predicted: now what? - Invezz
- 5 days ago - Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling - GlobeNewsWire
- 6 days ago - BrewDog USA Doubles Down on Headliners and Ignites Next Wave of Innovation for Spring and Summer - GlobeNewsWire
- 6 days ago - Tilray Brands (TLRY) Price Forecast: Cannabis Rescheduling Fuels Recovery - FXEmpire